
# The most complete service at the highest quality standards

Eurofins stands for a conception of clinical diagnostics entirely focused on excellence, innovation and technological investment. With tens of thousands of clinical diagnostic tests performed every day, we strive to ensure that every patient, wherever he or she lives, is assured access to the most specialized and most innovative techniques for diagnosis, monitoring and therapeutic adjustment. Eurofins clinical diagnostics offers testing services in all medical specialties, from routine testing to esoteric testing including genetic testing.



The commitment of our laboratories: with our logistics expertise and our daily sample collection and delivery network, we guarantee perfect continuity in the provision of care, and the same quality and access to innovation across all the regions that we serve. It is our mission to offer the most innovative tests to the wider population at a cost that is affordable for society.

## Cardiology by Eurofins Clinical Diagnostics









## Assessing cardiovascular risk with Eurofins exclusive tests

High density and low density lipoproteins (HDL, LDL) have been used for many years as indicators of cardiovascular disease (CVD) risk. However, most patients with heart disease do not have a classic lipid disorder or elevated LDL values. At Eurofins Clinical Diagnostics we have developed exclusive tests that allow a deeper understanding of CVD.

#### Predisposition testing

We offer genetic tests to evaluate predisposition towards heart disease for individuals with a family history of sudden cardiac death (including sudden infant death), heart failure or transplant. Genetic testing is also used as prevention in cases of professional or amateur agonistic activity, young individuals with idiopathic cardiac symptomatology, and children with suspected QT anomalies or cardiac rhythm.

#### Risk assessment

Proper assessment of CVD risk requires non-standard lipid panels that take into account HDL subpopulations. Eurofins HDL Map® takes into account the impact of the different particle sizes, composition and characteristics of those subpopulations on CVD risk. We also offer assessment of cardiometabolic syndrome (CMS) risk with a particular focus on prediabetes assessment.

#### **Diagnostics**

Both non-standard lipids panels and genetic tests are used to provide a diagnosis. Eurofins innovative tests allow for earlier diagnosis of CVD risk and therefore better care and prognosis of patients with a cardiovascular disorder.

## Designing a lifestyle plan for better prognosis

Results from Eurofins tests together with other factors such as health history, exercise and food preferences are used to define a personalized lifestyle program to help in reducing CVD risk. Enrollment in our lifestyle program has proven to have an impact on important biomarkers related to CVD risk.

#### Treatment personalization

An understanding of metabolic pathways for production and absorption of cholesterol allow us to design the best cholesterol lowering therapy based on statins, ezetimibe, PCSK9 inhibitors, probiotics, and bile acid sequestrants. Eurofins exclusive Statin Induced Myopathy (SLCO1B1) Genotype test is used to aid in the selection of the appropriate statin for treatment, to minimize side effects and increase treatment adherence.

#### Improving prognosis

We offer testing for several markers that are related with disease progression and patient prognosis. Inflammation markers such as High Sensitivity C-Reactive Protein (hs-CRP), provide independent prognostic information after initiating treatment. Aortic stenosis progression as well as prediction of hospital readmission and mortality can also be evaluated with Eurofins tests.



## Eurofins Clinical Diagnostics at the heart of the matter

#### 2. RISK ASSESSMENT

II | | | | | | | |

Exclusive tests to assess cardiovascular and cardiometabolic risk:

- HDL Map<sup>®</sup>
- Fatty Acid Balance<sup>TM</sup> test
- Prediabetes Assessment<sup>™</sup>

### 3. DIAGNOSTICS Biomarkers, non-standard lipid

panels and genetic tests to confirm diagnosis and decide on the best course of action i.e. medication

# PREDISPOSITION TREATMENT PREDISPOSITION ASSESSMENT DIAGNOSTICS DIAGNOSTICS ASSENDENT ASSESSMENT ASSESSMENT TREATMENT ASSESSMENT ASSESSMENT

#### 4. TREATMENT PERSONALIZATION

Eurofins offers exclusive tests to adapt medication to each patient's genetic and metabolic profile:

- Cholesterol Balance® test
   (biomarkers analyzed: lathosterol, desmosterol, beta-sitosterol, campesterol and cholesterol)
- Statin Induced Myopathy (SLC01B1) Genotype test
- Pharmacogenetic tests for anticoagulants, antiplatelet medication, hypolipidemic drugs and oral hypoglycemic drug response

#### 1. PREDISPOSITION

Single gene tests, extended genetic panels and clinical exome to evaluate predisposition to:

- Cardiomyopathies
- Channelopathies
- Connective tissue diseases
- Familial hypercholesterolemiaDiabetes MODY
- Sudden cardiac arrest

#### 5. PROGNOSIS

- Inflammation markers to evaluate patient prognosis (hs-CRP, LpPLA<sub>2</sub>, MPO)
- NT-proBNP marker as predictor of
- hospital readmission and mortality

  HDL Map® test to inform on aortic
- stenosis progression
- Design of a lifestyle program based on patient's individual cardiovascular disease (CVD) risk and cardiometabolic syndrome (CMS) risk

🔅 eurofins |

Clinical Diagnostic

LpPLA<sub>2</sub>: Lipoprotein-associated phospholipase A2
MPO: Myeloperoxidase
NT-proBNP: N-Terminal Pro-B-Type Natriuretic Peptide

HOMA-IR insulin resistance score

• Inflammation tests (fibrinogen,

• Adiponectin, insulin and homocysteine